|
시장보고서
상품코드
2058407
전립선암 치료제 시장 : 약제 종류별, 유통 채널별, 지역별Prostate Cancer Therapeutics Market, By Drug Type, By Distribution Channel, By Geography |
||||||
전립선암 치료제 시장은 2026년에 222억 달러로 추정되며, 2033년까지 293억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 8.1%로 성장할 것으로 전망됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 222억 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 8.10% | 2033년 시장 규모 예측: | 293억 달러 |
전립선암은 고령 남성에게서 가장 흔한 암입니다. 특히 고령 남성의 발병률이 높은 선진국에서 이는 심각한 건강 문제로 대두되고 있습니다. 유럽비뇨기과학회(EAU)의 2016년 보고서에 따르면, 발병률은 북유럽 및 서유럽에서 가장 높으며(70세 이상 남성 10만 명당 200명을 초과), 반면 동유럽 및 남유럽에서는 발병률이 지속적으로 증가하고 있습니다. 따라서, 충족되지 않은 의료적 요구를 해결하고 만족스러운 결과를 얻기 위해서는 전립선암 환자를 위한 혁신적인 약물의 도입이 요구되고 있습니다. 현재 전이성 거세저항성 전립선암(CRPC)은 일반적으로 화학요법(도세탁셀, 카바도세탁셀)이나 아비라테론, 트립토렐린 등의 2차 호르몬 요법제로 치료되고 있습니다. 시플루에셀-T를 이용한 면역요법은 내장 전이가 없는 무증상 또는 경증의 전이성 CRPC 치료에 처방됩니다.
시장 역학
연구 기관과 대학의 이러한 종양 치료제 개발을 위한 지속적인 투자 덕분에 시장은 놀라운 성장세를 보이고 있습니다. 이 새로운 치료법은 주로 거세 저항성 환자를 대상으로 승인되었으며, 지티가, 엑스탄디, 도세탁셀 제네릭과 같은 기존 치료법과 경쟁하거나, 기존 치료법의 보조 요법으로 기능할 것으로 기대됩니다. 예를 들어, 메트포르민(만수라 대학교), 아벨마브(듀크 대학교 의료센터), LY2452473(다나-파버 암 연구소) 등 2상 임상시험 단계에 있으며, 가까운 시일 내에 시장에 출시될 것으로 예상되는 유망한 파이프라인 제품들이 있습니다. 그러나 약제 비용의 상승이나 부작용이 시장 성장을 저해할 가능성이 있습니다.
본 조사의 주요 특징:
- 본 조사에서는 각 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 시장 억제요인, 기회, 신제품 출시 및 승인, 지역별 전망, 그리고 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 다음의 매개변수를 바탕으로 전 세계 전립선암 치료제 시장의 주요 기업 개요을 작성했습니다. 구체적으로는 기업 개요, 재무 실적, 제품 포트폴리오, 지리적 확장, 유통 전략, 주요 발전 및 전략, 그리고 향후 계획입니다.
- 본 보고서의 인사이트를 활용함으로써, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 유통 채널 강화, 시장 확대 및 마케팅 전략과 관련하여 정보에 기반한 의사결정을 내릴 수 있게 됩니다.
- 본 전립선암 치료제 시장 보고서는 투자자, 제품 제조사, 유통업체, 공급업체, 조사 및 컨설팅 회사, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 전립선암 치료제 시장 분석에 사용되는 다양한 전략 매트릭스는 이해관계자들에게 이에 따른 전략적 결정을 내리는 데 필요한 중요한 정보를 제공합니다.
목차
제1장 조사 목적과 가정
제2장 시장 개요
제3장 시장 역학·규제·동향 분석
제4장 세계의 전립선암 치료제 시장 : 약물 유형별, 2021-2033년
제5장 세계의 전립선암 치료제 시장 : 유통 채널별, 2021-2033년
제6장 세계의 전립선암 치료제 시장 : 지역별, 2021-2033년
제7장 경쟁 구도
제8장 섹션
KSM 26.06.19Prostate Cancer Therapeutics Market is estimated to be valued at USD 22.2 Bn in 2026 and is expected to reach USD 29.3 Bn by 2033, growing at a compound annual growth rate (CAGR) of 8.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 22.2 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.10% | 2033 Value Projection: | USD 29.3 Bn |
Prostate cancer is the most common cancer among the geriatric male population. It is a major health concern, especially in developed countries with a greater proportion of elderly men being affected by it. According to European Association of Urology, 2016, the incidence is highest in Northern and Western Europe (> 200 per 100,000 men with age group > 70 years of age), while rates in Eastern and Southern Europe have showed a continuous increase. Thus, the introduction of innovative drugs for patients with prostate cancer is required to meet the unmet needs with satisfactory results. Currently, metastatic castration-resistant prostate cancer (CRPC) is usually treated with chemotherapy (docetaxel, and cabazitaxel) or secondary hormonal therapeutic agents such as abiraterone or Triptorelin. Immunotherapy with Sipuleucel-T is prescribed in treating asymptomatic or minimally metastatic CRPC without visceral metastasis.
Market Dynamics
The market is gaining significant traction due to continuous investment by research organizations and universities for the development of therapeutic products for the treatment of such tumors. Novel therapies are expected to be predominately approved in castration-resistant patients, and to compete with better-established treatments, such as Zytiga, Xtandi and generic docetaxel, or to act as adjuvants to established therapies. For instance, there is a strong pipeline of products such as Metformin (Mansoura University), Avelumab (Duke University Medical Center), LY2452473 (Dana-Farber Cancer Institute), which are in their phase 2 studies and are projected to enter the market in the near future. However, high cost and side effects associated with drugs can restraint the market growth.
Key features of the study:
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
- It profiles leading players in the global prostate cancer therapeutics market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies and future plans
- Key companies covered as a part of this study include Johnson & Johnson, Astella, Inc, Sanofi-Aventis, Bayer AG, AstraZeneca Plc, Pfizer Inc., Dendreon Corporation (Sanpower Group Co. Ltd.), Ipsen Group, Tolmar Inc, Endo Pharmaceuticals, AbbVie, Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion and marketing tactics.
- The global prostate cancer therapeutics market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers for prostate cancer therapeutics market, research and consulting firms, new entrants and financial analysts
- Various strategy matrices used in analyzing the prostate cancer therapeutics market would provide stakeholders vital inputs to make strategic decisions accordingly
Market Segmentation
- By Drug Type (Revenue, USD Bn, 2021-2033)
- Hormonal Therapy
- Anti-androgens
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- By Distribution Channel (Revenue, USD Bn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Johnson & Johnson
- Astella, Inc
- Sanofi-Aventis
- Bayer AG
- AstraZeneca Plc
- Pfizer Inc.
- Dendreon Corporation (Sanpower Group Co. Ltd.)
- Ipsen Group
- Tolmar Inc
- Endo Pharmaceuticals
- AbbVie, Inc.
Table of Contents
1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Regulatory Scenario
- Reimbursement Scenario
- Pipeline Analysis
- PEST Analysis
- PORTER'S Five Forces
4. Global Prostate Cancer Therapeutics Market, By Drug Type, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hormonal Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Anti-Androgens
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
5. Global Prostate Cancer Therapeutics Market, By Distribution Channel, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Bn)
6. Global Prostate Cancer Therapeutics Market, By Region, 2021-2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2022-2033
- North America
- Market Size and Forecast, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
- Brazil
- Mexico
- Rest of Latin America
- Africa
- Market Size and Forecast, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
- Northern Africa
- Central Africa
- South Africa
- Middle East
- Market Size and Forecast, By Drug Type, 2021-2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021-2033, (USD Bn)
- Market Size and Forecast, By Country, 2021-2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
7. Competitive Landscape
- Heat Map Analysis
- Company Profiles
- Johnson & Johnson
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Astellas Pharma, Inc
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Sanofi
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Bayer AG
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AstraZeneca Plc
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Pfizer, Inc.
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Dendreon Corporation (Sanpower Group Co. Ltd.)
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Ipsen Group
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Tolmar Inc
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Endo International plc
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- AbbVie, Inc.
- Company Overview
- Technology Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Johnson & Johnson
8. Section
- Analyst Views
- Research Methodology
- About Us and Sales Contact
